Literature DB >> 1157572

Pharmacokinetic studies with mecillinam and pivmecillinam.

K Roholt, B Nielsen.   

Abstract

Mecillinam (FL 1060) is a new beta-lactam antibiotic particularly active against gram-negative organisms. When given intravenously, very high serum levels were maintained for a short period of time. Lower peak levels but comparable bioavailability were obtained after intramuscular administration. Gastrointestinal absorption of mecillinam is poor, and for effective oral therapy the drug must be given in the form of its pivaloyl-oxymethyl ester pivmecillinam (FL 1039) which is well absorbed and rapidly transformed to mecillinam by enzymatic hydrolysis in the body. Urinary recovery of mecillinam after orally administered pivmecillinam was 45% in the first 6 h compared with 55 and 59% after mecillinam given by the intravenous and intramuscular routes, respectively. By increasing the dose the orally active ester produced proportionally higher levels of mecillinam, and the area under the serum curve was doubled with the dose. Higher peak levels and prolonged maintenance of high serum concentrations were seen after administration of pivmecillinam with probenecid. The presence of food in the stomach did not influence the absorption of pivmecillinam to any great extent.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1157572     DOI: 10.1159/000221856

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  20 in total

1.  Factors influencing the absorption and disposition of mecillinam and pivmecillinam in man.

Authors:  J Andrews; M J Kendall; M Mitchard
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

2.  Drug treatment of typhoid fever.

Authors:  C H Herzog
Journal:  Br Med J       Date:  1976-10-16

3.  Growth properties of mecillinam-resistant bacterial variants in urine.

Authors:  J D Anderson; M A Adams; H M Webster; L Smith
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

4.  Pivmecillinam treatment of chronic urinary tract infection.

Authors:  T Kalager; E Bøe; A Digranes; P Høisaether; C O Solberg
Journal:  Infection       Date:  1978       Impact factor: 3.553

5.  Mecillinam in urinary tract infections and in septicaemia.

Authors:  N Frimodt-Møller; T J Ravn
Journal:  Infection       Date:  1979       Impact factor: 3.553

6.  In vitro activity of mecillinam against anaerobic bacteria.

Authors:  G E Steinkraus; L R McCarthy
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

7.  Pharmacokinetics of bacmecillinam and pivmecillinam in volunteers.

Authors:  K Josefsson; T Bergan; L Magni; B G Pring; D Westerlund
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Mecillinam: a new antibiotic for enteric fever.

Authors:  P D Clarke; A M Geddes; D McGhie; J C Wall
Journal:  Br Med J       Date:  1976-07-03

9.  Influence of food on bioavailability of amdinocillin pivoxil.

Authors:  L D Bornemann; S Castellano; A H Lin; D Enthoven; I H Patel
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Synergy of mecillinam, a beta-amidinopenicillanic acid derivative, combined with beta-lactam antibiotics.

Authors:  J C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.